Completed PHASE2 INTERVENTIONAL 1-arm NCT01062490

Treosulfan Based Conditioning Myelodysplastic Syndrome (MDS)

Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS)

Sponsor: medac GmbH

Conditions Myelodysplastic Syndrome

Interventions Treosulfan

Updated 5 times since 2017 Last updated: Feb 3, 2010 Started: Nov 30, 2004 Primary completion: Jul 31, 2008 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Myelodysplastic Syndrome, this trial is completed. The trial is conducted by medac GmbH and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Feb 2017 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

medac GmbH

Data source: medac GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Helsinki, Finland